Drug intelligence / Profile preview

ceralifimod

Development stage: Discontinued
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Ceralifimod is an oral, selective small molecule agonist of the sphingosine 1-phosphate (S1P) receptors S1P1 and S1P5, with high selectivity over other S1P receptor subtypes. It was developed primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS). By activating S1P1 and S1P5 receptors, ceralifimod modulates lymphocyte trafficking, reducing their egress from lymph nodes and thereby limiting autoimmune-mediated damage in multiple sclerosis. The drug reached phase 2/3 clinical trials but development was discontinued after termination of phase III studies. Ceralifimod was originally developed by Ono Pharmaceutical[3][4][5][7].

Other names: CeralifimodONO 4641ONO4641ONO-4641BZ2O8A84A4BZ-2O8A84A4BZ 2O8A84A4

Targets

S1PR5 (Sphingosine-1-phosphate receptor 5)

Beyond the preview

Go deeper on ceralifimod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceralifimod.

Explore the full profile